Frequent glucose monitoring and dose adjustment may be necessary for BASAGLAR in patients with renal impairment [see Warnings and Precautions (5.3)]
No other approved or investigational obesity therapy has matched the 24% figure at any dose in a published trial of comparable design
Disclaimer: This article is for informational purposes only and does not constitute medical, pharmaceutical, or insurance advice
Q: How and when to consume
Practitioners associate long-term use of Ozempic with gallbladder problems, pancreatitis, diabetic retinopathy progression, thyroid tumor risk (in animals), and kidney injury linked to dehydration
The GLP-1 Bridge program will cover three drugs, Foundayo, Wegovy and Zepbound, and be available to people who have Medicare Part D, an optional extra coverage to lower the cost of prescriptions